MOTS-c vs Tirzepatide.
Quick Verdict
MOTS-c is a mitochondrial peptide primarily researched for energy, metabolism, fat loss, longevity, while Tirzepatide is a dual agonist (glp-1/gip) studied for weight loss, body recomposition, glycemic control. A key distinction: Tirzepatide has FDA approval status.
Side-by-Side Analysis
| Dimension | MOTS-c | Tirzepatide |
|---|---|---|
| Category | Mitochondrial Peptide | Dual Agonist (GLP-1/GIP) |
| Mechanism | Regulates mitochondrial function and AMPK. | Dual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function. |
| Half-Life | ~4 hours | ~5 days |
| Route | SubQ | SubQ |
| Typical Dose | 2000–2000 mcg | 2500–2500 mcg |
| Frequency | 5x/week | 1x/wk |
| Evidence Level | Emerging | Very Strong |
| Indexed Studies | 20+ indexed | 20+ indexed |
| FDA Status | Research Only | Approved |
| Lowest Price | $39.99 / 10mg via Amino Club | $69.99 / 5mg via Amino Club |
| Per-mg Cost | $4.00/mg | $14.00/mg |
Mechanism of Action Comparison
How MOTS-c Works
MOTS-c MOTS-c is a peptide encoded in mitochondrial DNA studied for improving insulin sensitivity, boosting exercise performance, and protecting against the metabolic decline that comes with aging.
Regulates mitochondrial function and AMPK. Enhances glucose uptake and fatty acid oxidation, improves insulin sensitivity, and protects against age-related metabolic decline.
How Tirzepatide Works
Tirzepatide Tirzepatide is an FDA-approved dual GLP-1/GIP agonist sold as Mounjaro for type 2 diabetes and Zepbound for obesity, achieving up to 22.5% body weight loss in clinical trials.
Dual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function.
Key Mechanistic Difference
MOTS-c operates as a mitochondrial peptide, while Tirzepatide functions as a dual agonist (glp-1/gip) — these are fundamentally different pharmacological approaches. Tirzepatide has a significantly longer half-life (~5 days) compared to MOTS-c (~4 hours), which impacts dosing frequency and sustained activity.
Research Evidence
MOTS-c
20 studies- MOTS-c regulates metabolic homeostasis (Cell Metabolism)Lee et al. (Cell Metabolism): Discovery paper showing MOTS-c is a mitochondrial-derived peptide that regulates insulin s…Emerging
- MOTS-c prevents age-related insulin resistance in miceLee et al.: MOTS-c treatment prevents both age-dependent and high-fat-diet-induced insulin resistance and diet-induced o…Preclinical
- MOTS-c improves skeletal muscle glucose metabolismStudy demonstrating MOTS-c specifically targets skeletal muscle glucose metabolism, providing molecular basis for metabo…Preclinical
Tirzepatide
20 studies- Tirzepatide Phase 3 SURMOUNT-1: up to 22.5% weight lossJastreboff et al. (NEJM): Phase 3 SURMOUNT-1 trial tirzepatide 15mg achieved 22.5% body weight reduction vs 2.4% place…Very Strong
- SURMOUNT-4: 176-week long-term weight maintenanceAronne et al.: 176-week data showing sustained weight loss maintenance with continued tirzepatide treatment 15mg dose …Very Strong
- Tirzepatide meta-analysis: BMI, weight, and metabolic outcomesMeta-analysis of multiple RCTs confirming tirzepatide significantly reduces BMI, waist circumference, body weight, and H…Very Strong
Vendor Pricing
· Affiliate links · Prices verified 2026MOTS-c
4 vendorsTirzepatide
2 vendorsAffiliate disclosure: PeptiDex may earn a commission from purchases via vendor links at no extra cost to you. See our methodology.
Frequently Asked Questions
Can I take MOTS-c and Tirzepatide together?▼
No direct interaction data is available for this specific pair. They target different receptor systems, suggesting they could potentially be combined, but no published protocol validates this combination.
Which has more research evidence — MOTS-c or Tirzepatide?▼
MOTS-c has 20 indexed studies (highest evidence: Emerging). Tirzepatide has 20 indexed studies (highest evidence: Very Strong). Both have comparable research coverage.
What is the price difference between MOTS-c and Tirzepatide?▼
At current verified vendor prices, MOTS-c starts at $4.00/mg while Tirzepatide starts at $14.00/mg. Prices vary by vendor and vial size — see the full vendor comparison below.
Which is better for fat loss — MOTS-c or Tirzepatide?▼
Both are researched for fat loss. MOTS-c addresses this via energy, metabolism, fat loss, longevity. Tirzepatide approaches it through weight loss, body recomposition, glycemic control. The optimal choice depends on your specific research protocol and which mechanism aligns with your objectives.
Is MOTS-c or Tirzepatide FDA-approved?▼
Tirzepatide has FDA approval (or is derived from an FDA-approved compound). MOTS-c is a research compound without FDA approval for human use. FDA status reflects regulatory evaluation — not necessarily superiority for all research applications.
Related Comparisons
Deep Dive Profiles
Shared Research Goals
Research Use Only — Not Medical Advice
This comparison is provided for educational and research purposes only. It does not constitute medical, prescribing, or treatment advice. Clinical data cited here is sourced from published peer-reviewed trials and FDA labels. Consult a qualified healthcare professional before making any decisions about medications or research compounds. PeptiDex is an informational resource and does not sell pharmaceutical products.